Wall Street Zen Upgrades Bayer Aktiengesellschaft (OTCMKTS:BAYRY) to "Buy"

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Thursday.

Several other brokerages have also recently commented on BAYRY. The Goldman Sachs Group raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. Hsbc Global Res raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Wednesday, June 11th. Finally, Kepler Capital Markets raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Wednesday, June 11th. One analyst has rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy".

Bayer Aktiengesellschaft Stock Down 0.4%

Bayer Aktiengesellschaft stock opened at $7.67 on Thursday. The firm has a 50 day simple moving average of $6.99 and a 200 day simple moving average of $6.10. The company has a current ratio of 1.25, a quick ratio of 0.79 and a debt-to-equity ratio of 1.07. Bayer Aktiengesellschaft has a 1-year low of $4.79 and a 1-year high of $8.58. The firm has a market capitalization of $30.14 billion, a price-to-earnings ratio of -8.34 and a beta of 0.85.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.02. The company had revenue of $15.27 billion during the quarter, compared to analysts' expectations of $13.39 billion. Bayer Aktiengesellschaft had a positive return on equity of 13.94% and a negative net margin of 7.26%. On average, analysts predict that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.